Meet Glyphic Biotechnologies 🧬, Revolutionizing Protein Detection

Meet Josh and Daniel — the team bringing protein detection to the frontline.

Daniel Estandian and Josh Yang, founders of Glyphic Biotechnologies.

What is Glyphic Biotechnologies?

Glyphic Biotechnologies is decoding the human proteome through full coverage, de novo protein sequencing at single molecule resolutions, advancing beyond the decades old technologies based on mass spectrometry and ELISAs. Although decoding the human genome through the invention of DNA sequencing has ushered in a new era of biomedical sciences, this blueprint is not enough. We are defined by more than our genes: to understand the human body, we must understand the proteins that actually perform our day-to-day functions — and malfunctions. Our platform will enable the development of novel therapeutics and diagnostics and, ultimately, a deeper understanding of human biology.

What’s next for your team?

We are closing our oversubscribed seed round that will support R&D efforts to de-risk the platform. After this period of development, we will move into instrument design and manufacturing, bringing us one step closer to the commercial launch.

What the team has and what they are looking for:

Josh is a Stanford GSB MBA student (’21) and Daniel is a MIT PhD student (‘21). We are looking for people with backgrounds in biotechnology platform product management and instrumentation / systems integration engineering. If that sounds like you send me an email: joshua@glyphic.bio.

Fun fact!

We may be one of the first venture-backed startups where the co-founders had never physically met each other prior to closing their first fundraising round!